JP2025508324A5 - - Google Patents
Info
- Publication number
- JP2025508324A5 JP2025508324A5 JP2024543863A JP2024543863A JP2025508324A5 JP 2025508324 A5 JP2025508324 A5 JP 2025508324A5 JP 2024543863 A JP2024543863 A JP 2024543863A JP 2024543863 A JP2024543863 A JP 2024543863A JP 2025508324 A5 JP2025508324 A5 JP 2025508324A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- nucleotides
- dsrna
- pkk
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/074535 | 2022-01-28 | ||
| CN2022074535 | 2022-01-28 | ||
| PCT/CN2023/073501 WO2023143483A1 (en) | 2022-01-28 | 2023-01-28 | Compositions and methods for inhibiting expression of prekallikrein (pkk) protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508324A JP2025508324A (ja) | 2025-03-26 |
| JP2025508324A5 true JP2025508324A5 (enExample) | 2026-02-02 |
Family
ID=87470605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543863A Pending JP2025508324A (ja) | 2022-01-28 | 2023-01-28 | プレカリクレイン（ｐｋｋ）タンパク質の発現を阻害するための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250145999A1 (enExample) |
| EP (1) | EP4469570A4 (enExample) |
| JP (1) | JP2025508324A (enExample) |
| KR (1) | KR20240139057A (enExample) |
| CN (1) | CN118510894A (enExample) |
| AU (1) | AU2023210979A1 (enExample) |
| CA (1) | CA3244243A1 (enExample) |
| IL (1) | IL314396A (enExample) |
| MX (1) | MX2024009257A (enExample) |
| TW (1) | TW202346586A (enExample) |
| WO (1) | WO2023143483A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022357561A1 (en) * | 2021-10-01 | 2024-04-18 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670492B2 (en) * | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| CA2984636A1 (en) * | 2015-05-06 | 2016-11-10 | Alnylam Pharmaceuticals, Inc. | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
| EP3649243A1 (en) * | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| CN109762904A (zh) * | 2019-03-05 | 2019-05-17 | 中国医学科学院北京协和医院 | 与胰腺神经内分泌肿瘤相关的分子标记物及其应用 |
| CN113891939B (zh) * | 2019-05-24 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN115176007A (zh) * | 2019-12-16 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | 含类PATATIN磷脂酶结构域3(PNPLA3)iRNA组合物及其使用方法 |
| CN115362256A (zh) * | 2020-02-07 | 2022-11-18 | 因特利亚治疗公司 | 用于激肽释放酶（klkb1）基因编辑的组合物和方法 |
| AU2022357561A1 (en) * | 2021-10-01 | 2024-04-18 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
-
2023
- 2023-01-19 TW TW112102528A patent/TW202346586A/zh unknown
- 2023-01-28 EP EP23746361.7A patent/EP4469570A4/en active Pending
- 2023-01-28 MX MX2024009257A patent/MX2024009257A/es unknown
- 2023-01-28 IL IL314396A patent/IL314396A/en unknown
- 2023-01-28 CA CA3244243A patent/CA3244243A1/en active Pending
- 2023-01-28 KR KR1020247025383A patent/KR20240139057A/ko active Pending
- 2023-01-28 AU AU2023210979A patent/AU2023210979A1/en active Pending
- 2023-01-28 CN CN202380015864.8A patent/CN118510894A/zh active Pending
- 2023-01-28 WO PCT/CN2023/073501 patent/WO2023143483A1/en not_active Ceased
- 2023-01-28 JP JP2024543863A patent/JP2025508324A/ja active Pending
- 2023-01-28 US US18/833,727 patent/US20250145999A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6991966B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2025504863A5 (enExample) | ||
| JP2025134688A (ja) | α－１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2023103244A5 (enExample) | ||
| JP7798881B2 (ja) | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 | |
| JP2024543496A5 (enExample) | ||
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| JP2021518125A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2018519797A5 (enExample) | ||
| CN1980947A (zh) | 改良的凝血因子调节物 | |
| IL310929A (en) | Preparations and methods for inhibiting expression of angiopoietin-like protein 3 | |
| JP2024508896A5 (enExample) | ||
| JP2024523000A5 (enExample) | ||
| GB2635479A (en) | Dual silencing | |
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| IL314396A (en) | Preparations and methods for inhibiting the expression of the parakallikrein protein (PKK) | |
| JP2025527670A (ja) | Ａｎｇｐｔｌ３関連疾患及び障害の治療方法 | |
| JP7846095B2 (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| JP2024534766A5 (enExample) | ||
| RU2024121070A (ru) | Композиции и способы ингибирования экспрессии белка прекалликреина (ркк) | |
| JP2022546570A5 (enExample) | ||
| KR20130121448A (ko) | ｍｉＲ－21 억제제를 유효성분으로 포함하는 허혈성 질환의 예방 또는 치료용 조성물 |